Compositions for caring for keratin materials

Abstract

Provided herein are compositions for caring for keratin materials comprising: (i) at least one Saccharomyces cerevisiae extract; (ii) at least one compound selected from vitamin B3 and derivatives thereof; (iii) at least one divalent metal salt; and (iv) at least one monosaccharide selected from the group consisting of mannose, glucose, galactose, fructose, and combinations thereof. The invention also relates to a non-therapeutic method for caring for a keratin material comprising applying the composition to a keratin material.

Description

Technical Field

[0001] The present invention relates to cosmetic compositions. In particular, the present invention relates to compositions for caring for keratin materials. The present invention also relates to non-therapeutic methods for caring for keratin materials. Background Art

[0002] Human skin is composed of three compartments, namely, a superficial compartment, which is the epidermis; a dermis; and a deep compartment, which is the subcutaneous tissue.

[0003] The dermis is mainly composed of fibroblasts and an extracellular matrix (ECM). This extracellular matrix is ​​composed of various macromolecules that are responsible for the mechanical strength of the skin, its flexibility, its tonicity and its elasticity, and are also responsible for physiologically important functions (hydration, thermoregulation and regulation of skin permeability). These macromolecules include, in particular, collagen, elastin and glycoconjugates (glycoproteins and proteoglycans).

[0004] Collagen makes up 70% of the proteins in the ECM. Naturally, collagen is constantly renewed, but this turnover decreases with age, which leads to thinning of the dermis.

[0005] It is also known that prolonged exposure to ultraviolet radiation (especially type A and B radiation) has the effect of stimulating the expression of collagenases, especially MMPI (also known as matrix metalloproteinase 1 or interstitial collagenase), which constitutes one of the components of light-induced or non-light-induced skin aging.

[0006] Various cosmetic products have been used to care for the skin, for example to combat skin aging. However, some cosmetic products do not provide a good skin feel after application.

[0007] Therefore, there remains a need to formulate compositions for the care of the skin that are effective in combating skin aging and that provide a good skin feel after application. Summary of the Invention

[0008] It was therefore an object of the present invention to develop a composition for caring for the skin which effectively combats skin aging and provides a good skin feel after application.

[0009] Another object of the present invention is to provide a cosmetic method for caring for the skin.

[0010] The inventors have now found that it is possible to formulate compositions for the care of the skin which are effective in combating skin ageing and which provide a good skin feel after application.

[0011] Thus, in a first aspect, the present invention provides a composition for caring for keratin materials comprising: (i) at least one Saccharomyces cerevisiae extract; (ii) at least one compound selected from vitamin B3 and its derivatives; (iii) at least one divalent metal salt; and (iv) at least one monosaccharide selected from the group consisting of mannose, glucose, galactose, fructose, and combinations thereof.

[0012] The inventors have found that the composition of the present invention can inhibit the production of MMP-1 and effectively resist skin aging.

[0013] The inventors have also found that the compositions of the present invention can also provide a good smooth and soft feel.

[0014] In a second aspect, the present invention provides a non-therapeutic method for caring for keratin materials, which comprises applying to the keratin material a composition according to the first aspect of the invention.

[0015] Other subjects and features, aspects and advantages of the invention will appear even more clearly on reading the following description and examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Implementation of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which: Figure 1 Shown are the MMP-1 levels of cells from different groups tested in vitro. DETAILED DESCRIPTION

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. When the definition of a term in this specification conflicts with the meaning commonly understood by those skilled in the art to which this invention belongs, the definition described in this specification shall apply.

[0018] In the following and unless otherwise indicated, the limits of a range of values ​​are included in the range, especially in the expressions "between and" and "ranging from to".

[0019] In addition, the expression "at least one" used in this specification is equivalent to the expression "one or more".

[0020] Throughout this application, the term "comprising" should be interpreted as encompassing all specifically mentioned features as well as optional, additional, unspecified features. As used herein, the use of the term "comprising" also discloses embodiments in which no other features than the specifically mentioned features are present (i.e., "consisting of").

[0021] Unless otherwise indicated, all numerical values ​​expressing quantities of ingredients and the like used in the specification and claims are to be understood as modified by the term “about.” Accordingly, unless indicated to the contrary, the numerical values ​​and parameters described herein are approximations that can vary as necessary depending on the desired purpose.

[0022] For the purposes of the present invention, the term "keratin material" is intended to encompass human skin, mucous membranes, such as lips. Facial skin is most particularly contemplated according to the present invention.

[0023] Unless otherwise specified, all percentages in the present invention are by weight.

[0024] According to a first aspect, the composition of the present invention comprises: (i) at least one Saccharomyces cerevisiae extract; (ii) at least one compound selected from vitamin B3 and its derivatives; (iii) at least one divalent metal salt; and (iv) at least one monosaccharide selected from the group consisting of mannose, glucose, galactose, fructose, and combinations thereof.

[0025] Saccharomyces cerevisiae extract According to a first aspect, the composition of the present invention comprises at least one Saccharomyces cerevisiae extract.

[0026] Preferably, the Saccharomyces cerevisiae extract is an extract of yeast cells of Saccharomyces cerevisiae.

[0027] The extract may not include any other parts or elements of the yeast, such as the walls or membranes of the yeast.

[0028] The extract can be obtained by a method comprising the following steps: a. dissolving at least 50 g / L of Saccharomyces cerevisiae in water by mechanical homogenization; b. separating the soluble phase from the insoluble phase; c. ultrafiltration and filtrate recovery; and d. molecular sorting, in particular molecular sorting by membrane filtration.

[0029] The extract may contain a protein fraction. The distribution and amount of the protein fraction can be determined by measuring total nitrogen according to the KJELDHAL method (reference: Official method of analysis of the AOC, 12th edition W Horwitz, ED, New-York, 15-60, 1975).

[0030] The extract may be in liquid or dry form.

[0031] As an example of a commercial product of Saccharomyces cerevisiae extract, mention may be made of the product sold by the company SILAB under the trade name Saccharomyces cerevisiae extract sold under the name.

[0032] Advantageously, the Saccharomyces cerevisiae extract is present in the composition in an amount ranging from 0.001 wt.% to 0.375 wt.%, preferably from 0.01 wt.% to 0.175 wt.%, more preferably from 0.05 wt.% to 0.1 wt.% of dry matter relative to the total weight of the composition of the invention.

[0033] Vitamin B3 and its derivatives According to a first aspect, the composition of the present invention comprises at least one compound selected from vitamin B3 and its derivatives.

[0034] Vitamin B3 (also known as vitamin PP) is a compound of the following formula (A): Wherein R can be -CONH2 (nicotinamide), -COOH (nicotinic acid or nicotinic acid), or CH2OH (nicotinyl alcohol), -CO-NH-CH2-COOH (nicotinuric acid) or -CO-NH-OH (nicotinyl hydroxamic acid).

[0035] Vitamin B3 derivatives that may be mentioned include, for example, nicotinic acid esters, such as tocopheryl nicotinate, amides derived from nicotinamide by substitution of the hydrogen group of -CONH2, products from reactions with carboxylic acids and amino acids, esters of nicotinyl alcohol with carboxylic acids, such as acetic acid, salicylic acid, glycolic acid or palmitic acid.

[0036] The following derivatives may also be mentioned: 2-chloronicotinamide, 6-methylnicotinamide, 6-aminonicotinamide, N-methylnicotinamide, N,N-dimethylnicotinamide, N-(hydroxymethyl)nicotinamide, quinolinic acid imide, nicotinanilide, N-benzylic acid amide, N-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, nialamide, 2-mercaptonicotinic acid, nicomol and niaprazine, methyl nicotinate and sodium nicotinate.

[0037] Other vitamin B3 derivatives that may be mentioned include its inorganic salts, such as chlorides, bromides, iodides or carbonates; and its organic salts, for example salts obtained by reaction with carboxylic acids, such as acetates, salicylates, glycolates, lactates, malates, citrates, mandelates, tartrates, etc.

[0038] In some embodiments, the compound selected from vitamin B3 and its derivatives is selected from niacinamide, nicotinic acid, nicotinyl alcohol, nicotinuric acid, nicotinyl hydroxamic acid, nicotinic acid esters, esters of nicotinyl alcohol with carboxylic acids, 2-chloronicotinamide, 6-methylnicotinamide, 6-aminonicotinamide, N-methylnicotinamide, N,N-dimethylnicotinamide, N-(hydroxymethyl)nicotinamide, quinolinic acid imide, nicotinanilide, N-benzylinotinamide, N-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, nyalamid, 2-mercaptonicotinic acid, nicotinamide and nyprazine, methyl nicotinate and sodium nicotinate, and combinations thereof.

[0039] In some preferred embodiments, the compound selected from vitamin B3 and its derivatives is selected from niacinamide, niacin, nicotinic alcohol, nicotinuric acid, nicotinyl hydroxamic acid, and combinations thereof.

[0040] In a more preferred embodiment, the compositions of the present invention comprise niacinamide.

[0041] Advantageously, the compound chosen from vitamin B3 and its derivatives is present in the composition of the invention in an amount ranging from 0.01 wt.% to 7 wt.%, preferably from 0.1 wt.% to 5 wt.%, more preferably from 0.5 wt.% to 3 wt.%, relative to the total weight of the composition.

[0042] Divalent metal salt According to a first aspect, the composition of the invention comprises at least one divalent metal salt.

[0043] The divalent metal salt contains a metal ion M1 2+ . Preferably, M1 2+ Selected from Mg 2+ , Ca 2+ 、Zn 2+ and Cu 2+ .

[0044] The divalent metal salt is selected from metal salts of organic or inorganic acids.

[0045] As examples of organic acids, there may be mentioned ascorbic acid, formic acid, acetic acid, glycolic acid, gluconic acid, aspartic acid, lactic acid, mandelic acid, oxalic acid, maleic acid, malonic acid, glyoxylic acid, succinic acid, adipic acid, fumaric acid, sebacic acid, citric acid, tartaric acid, malic acid, tricarboxylic acid, glutaric acid, saccharic acid, pyrrolidonecarboxylic acid, phenolsulfonic acid, salicylic acid, and the like.

[0046] As examples of the inorganic acid, there may be mentioned sulfuric acid, carbonic acid, silicic acid, hydrochloric acid, nitric acid, phosphoric acid and the like.

[0047] Preferably, the divalent metal salt of an inorganic acid is selected from metal chlorides, metal sulfates, metal nitrates, metal carbonates and metal bicarbonates, metal phosphates, metal silicates, and mixtures thereof, wherein the metal is selected from Mg, Ca, Zn and Cu.

[0048] More preferably, the divalent metal salt of an inorganic acid is selected from the group consisting of calcium chloride, calcium sulfate, calcium nitrate, calcium carbonate and bicarbonate, calcium phosphate, zinc chloride, zinc sulfate, zinc nitrate, zinc carbonate and bicarbonate, zinc phosphate, magnesium chloride, magnesium sulfate, magnesium nitrate, magnesium carbonate and bicarbonate, magnesium phosphate, copper chloride, copper sulfate, copper nitrate, copper carbonate and bicarbonate, copper phosphate, and mixtures thereof.

[0049] Preferably, the divalent metal salt of an organic acid is selected from the group consisting of metal ascorbates, metal formates, metal acetates, metal glycolates, metal aspartates, metal gluconates, metal lactates, metal mandelates, metal oxalates, metal maleates, metal malonates, metal glyoxylates, metal succinates, metal adipates, metal fumarates, metal sebacates, metal citrates, metal tartrates, metal malates, metal tricarboxylates, metal glutarates, metal glucarates, metal pyrrolidonecarboxylates, metal phenolsulfonates, metal salicylates, and mixtures thereof, wherein the metal is selected from the group consisting of Mg, Ca, Zn, and Cu.

[0050] More preferably, the divalent metal salt of an organic acid is selected from magnesium gluconate, magnesium aspartate, magnesium PCA (magnesium pyrrolidone carboxylate), magnesium acetate, calcium PCA (calcium pyrrolidone carboxylate), zinc lactate, zinc gluconate, zinc phenolsulfonate, zinc salicylate, zinc PCA (zinc pyrrolidone carboxylate), zinc citrate, zinc ascorbate, zinc aspartate, copper PCA (copper pyrrolidone carboxylate), copper gluconate, copper aspartate, and mixtures thereof.

[0051] According to a preferred embodiment, the divalent metal salt is selected from magnesium gluconate, magnesium aspartate, magnesium PCA, magnesium sulfate, magnesium acetate, magnesium carbonate, calcium carbonate, calcium PCA, calcium chloride, calcium carbonate, zinc PCA, zinc gluconate, copper PCA, copper gluconate, and mixtures thereof.

[0052] Advantageously, the divalent metal salt is present in the composition of the invention in an amount ranging from 0.00001 to 1 wt.%, preferably from 0.00005 to 0.5 wt.%, more preferably from 0.0001 to 0.1 wt.%, relative to the total weight of the composition.

[0053] monosaccharides According to a first aspect, the composition of the present invention comprises at least one monosaccharide selected from the group consisting of mannose, glucose, galactose, fructose, and combinations thereof.

[0054] In some embodiments, the composition according to the present invention comprises mannose, ie, a compound of the formula:

[0055] In some embodiments, the composition according to the present invention comprises glucose, ie, a compound of the formula:

[0056] In some embodiments, the composition according to the present invention comprises galactose, ie, a compound of the formula:

[0057] In some embodiments, the composition according to the present invention comprises fructose, ie, a compound of the formula:

[0058] Preferably, the composition comprises glucose.

[0059] Advantageously, the monosaccharide is present in the composition of the invention in an amount ranging from 0.01 to 2 wt.%, preferably from 0.05 to 1.5 wt.%, more preferably from 0.1 to 1 wt.%, relative to the total weight of the composition.

[0060] Water phase The compositions of the present invention may comprise an aqueous phase.

[0061] The aqueous phase comprises water.

[0062] Advantageously, water is present in the composition of the invention in an amount ranging from 50 wt.% to 98 wt.%, preferably from 60 wt.% to 95 wt.%, more preferably from 70 wt.% to 93 wt.% relative to the total weight of the composition.

[0063] Preferably, the aqueous phase comprises an organic solvent miscible with water (at room temperature 25° C.) to provide hydration, selected from the group consisting of mono-, di- and polyols having 2 to 20 carbon atoms, such as octyldodecanol, glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, diethylene glycol; and mixtures thereof.

[0064] If present, the water-miscible organic solvent chosen from mono-, di- and polyols is advantageously present in the composition in an amount ranging from 0.5 to 20 wt.%, preferably from 1 to 10 wt.%, relative to the total weight of the composition.

[0065] Preferably, the continuous aqueous phase of the composition of the present invention comprises water and glycerol.

[0066] oil phase The compositions of the present invention may comprise an oily phase.

[0067] The oily phase contains at least one oil, especially a cosmetic oil. It may also contain other fatty substances.

[0068] The term "oil" refers to a water-immiscible, non-aqueous compound that is liquid at room temperature (20°C) and atmospheric pressure (760 mmHg).

[0069] Oils can be volatile or non-volatile.

[0070] The term "non-volatile" means that its vapor pressure at room temperature and atmospheric pressure is not zero and is less than 10 -3 mmHg (0.13Pa) of oil.

[0071] For the purposes of the present invention, the term "volatile oil" means any oil that is capable of evaporating in less than one hour upon contact with the skin at room temperature and atmospheric pressure.

[0072] The oil phase may comprise hydrocarbon-based oils, silicone oils, or mixtures thereof.

[0073] They may be of animal, vegetable, mineral or synthetic origin.

[0074] For the purposes of the present invention, the term "silicone oil" denotes an oil comprising at least one silicon atom and in particular at least one Si-O group.

[0075] The term "hydrocarbon-based oil" means an oil containing mainly hydrogen and carbon atoms.

[0076] The oil may optionally contain oxygen atoms, nitrogen atoms, sulfur atoms and / or phosphorus atoms, for example in the form of hydroxyl groups or acid groups.

[0077] If present, the oily phase is advantageously present in the composition of the invention in an amount ranging from 0.1 wt.% to 5 wt.%, preferably from 0.2 wt.% to 2.5 wt.% relative to the total weight of the composition of the invention.

[0078] Additional cosmetic active ingredients The compositions according to the invention may comprise, in addition to the cosmetically active compounds of formula (I) as defined hereinbefore, further cosmetically active ingredients.

[0079] As examples of cosmetic active ingredients, mention may be made of moisturizers; vitamins, such as vitamin A (retinol), vitamin E (tocopherol), vitamin C (ascorbic acid), vitamin B5 (panthenol), and derivatives (especially esters) of said vitamins, and mixtures thereof; whitening agents; tightening agents; exfoliating agents; moisturizing and hydrating agents (HA), repairing and soothing agents; other anti-aging agents; agents acting on the microcirculation; and mixtures thereof.

[0080] A person skilled in the art can easily adjust the amount of additional cosmetic active ingredients based on the final use of the composition according to the invention.

[0081] Additional adjuvants or additives The composition of the present invention may further contain conventional cosmetic adjuvants or additives, such as fragrances, chelating agents, preservatives and bactericides, surfactants, thickeners, pH adjusters, and mixtures thereof.

[0082] A person skilled in the art can select the amount of further auxiliaries or additives such that the end use of the composition according to the invention is not adversely affected.

[0083] According to a particularly preferred embodiment, the present invention provides a composition for caring for keratin materials comprising, relative to the total weight of the composition: (i) 0.05 wt.% to 0.1 wt.% of at least one Saccharomyces cerevisiae extract; (ii) 0.5 wt.% to 3 wt.% of niacinamide; (iii) 0.0001 wt.% to 0.1 wt.% of at least one divalent metal salt selected from the group consisting of magnesium gluconate, magnesium aspartate, magnesium PCA, magnesium acetate, magnesium carbonate, calcium carbonate, calcium PCA, calcium chloride, calcium carbonate, zinc PCA, zinc gluconate, copper PCA, copper gluconate, and mixtures thereof; and (iv) 0.1 wt.% to 1 wt.% of glucose.

[0084] Galenic form and method The composition of the present invention is in the form of a lotion, cream, lotion or hydrogel.

[0085] The compositions according to the invention can be used for caring for keratin materials.

[0086] According to a second aspect, the present invention provides a non-therapeutic method for caring for keratin materials, which comprises applying to the keratin material a composition according to the first aspect of the invention.

[0087] In some embodiments, the present invention provides a non-therapeutic method for anti-aging of keratin materials, comprising applying a composition according to the first aspect of the invention to the keratin material.

[0088] In particular, the keratin material is skin. Example

[0089] The following examples are given as non-limiting illustrations of the present invention.

[0090] The main raw materials used, their trade names and suppliers are listed in Table 1. Table 1

[0091] Inventive Example 1 and Comparative Examples 1-4 The composition of Inventive Example (IE) 1 and the compositions of Comparative Examples (CE) 1-4 were prepared based on the amounts given in Table 2. The amounts are given as % by weight of active ingredient relative to the total weight of the composition. Table 2

[0092] Saccharomyces cerevisiae extract*: The amount indicates the amount of dry matter.

[0093] The composition of Inventive Example 1 represents a composition according to the present invention.

[0094] The composition of Comparative Example 1 does not include a divalent metal salt.

[0095] The composition of Comparative Example 2 does not contain Saccharomyces cerevisiae extract.

[0096] The composition of Comparative Example 3 does not contain a compound selected from vitamin B3 and its derivatives.

[0097] The composition of Comparative Example 4 does not include a monosaccharide selected from mannose, glucose, galactose, fructose, and combinations thereof.

[0098] Preparation method: The compositions listed above were prepared as follows: 1) Introduce the components of phase A1 into the main container while mixing and heat to 80°C for 6 minutes; 2) Introduce the components of phase A2 and phase A3 phase by phase while mixing to obtain a uniform mixture; 3). Slowly introduce phase B components (water) under mixing to dilute; and 4). When the temperature is lowered to about 40°C, the components of phase C, the components of phase D, the components of phase E and the components of phase F are introduced phase by phase under mixing to obtain respective compositions.

[0099] Evaluate In vitro testing Primary human dermal fibroblasts (HDF) were seeded in two 24-well plates (3 × 10 4 HDFs were placed in 500 μg / well cells and cultured in a cell culture medium (DMEM medium, 10% FBS, hereinafter referred to as standard medium) at 37°C in an incubator for 24 hours. HDFs were then divided into five groups and subjected to different treatments as follows.

[0100] The first group was treated with 0.3 wt.% (based on the total weight of the culture medium) of the composition of Comparative Example 1 for another 24 hours, then subjected to 10 J of UVA light, and finally treated with 0.3 wt.% of the composition of Comparative Example 1 for 48 hours.

[0101] The second group was treated with 0.3 wt. % of the composition of Inventive Example 1 for another 24 hours, then subjected to 10 J of UVA light, and finally treated with 0.3 wt. % of the composition of Inventive Example 1 for 48 hours.

[0102] The third group (as a positive control) was treated with 0.1 uM dexamethasone (DT, as a positive control) for another 24 hours, and then the human primary dermal fibroblasts were subjected to 10 J UVA light and finally treated with 0.1 uM dexamethasone for 48 hours.

[0103] The fourth group (serving as blank control A) was cultured with standard medium (ie, not treated with any composition or dexamethasone) for another 24 hours without being subjected to UVA light, and finally cultured with standard medium for 48 hours.

[0104] The fifth group (serving as blank control B) was cultured with standard medium (ie, not treated with any composition or dexamethasone) for another 24 hours, then subjected to UVA light, and finally cultured with standard medium for 48 hours.

[0105] Table 3 shows the groups using different treatment conditions. Table 3

[0106] Next, supplements from different groups were collected and tested for MMP-1 levels by ELISA (enzyme-linked immunosorbent assay).

[0107] Figure 1 Shown are the MMP-1 levels of cells from different groups tested in vitro.

[0108] from Figure 1 As can be seen in the figure, 10J UVA can trigger a 200% increase in MMP-1, and as a positive control, 0.1 μM dexamethasone (DT) can significantly reduce the release of MMP-1.

[0109] from Figure 1 As can be seen from the results, compared with the composition of Comparative Example 1, the composition of Inventive Example 1 can more significantly reverse the release of MMP-1 induced by UVA.

[0110] In vivo testing Ten experts applied two samples each time (one sample was the composition of Inventive Example 1 and the other sample was the composition of Comparative Example 1, 2, 3 or 4) on the back of the hand, and evaluated the skin finish in terms of softness and smoothness.

[0111] Compared with the composition of Comparative Example 1, five experts believed that the composition of Inventive Example 1 provided a better soft feel, four experts believed that there was no difference between the two compositions in terms of soft feel, and one expert believed that the composition of Comparative Example 1 was better than the composition of Inventive Example 1 in terms of soft feel, while six experts believed that the composition of Inventive Example 1 provided a better smooth feel, and four experts believed that there was no difference between the two compositions in terms of smooth feel.

[0112] Compared with the composition of Comparative Example 2, seven experts believed that the composition of Inventive Example 1 provided a better soft feel, and three experts believed that there was no difference in soft feel between the two compositions, while all 10 experts believed that the composition of Inventive Example 1 provided a better smooth feel.

[0113] Compared with the composition of Comparative Example 3, seven experts believed that the composition of Inventive Example 1 provided a better soft feel, and three experts believed that the composition of Comparative Example 3 was better than the composition of Inventive Example 1 in terms of soft feel, while five experts believed that the composition of Inventive Example 1 provided a better smooth feel, and five experts believed that the composition of Comparative Example 3 was better than the composition of Inventive Example 1 in terms of smooth feel.

[0114] Compared with the composition of Comparative Example 4, six experts believed that the composition of Inventive Example 1 provided a better soft feel, and four experts believed that the composition of Comparative Example 4 was better than the composition of Inventive Example 1 in terms of soft feel, while five experts believed that the composition of Inventive Example 1 provided a better smooth feel, and five experts believed that the composition of Comparative Example 4 was better than the composition of Inventive Example 1 in terms of smooth feel.

[0115] It can be seen that the composition of Inventive Example 1 provides a soft and smooth feel that is significantly better than the compositions of Comparative Example 1 and Comparative Example 2, a soft feel that is significantly better than the composition of Comparative Example 3, and a soft feel that is slightly better than the composition of Comparative Example 4.

[0116] In conclusion, the composition according to the present invention can inhibit the production of MMP-1, and thus can effectively resist skin aging, and at the same time, it can provide a good smooth and soft feeling.

Claims

1. A composition for caring for keratin materials, comprising: (i) at least one Saccharomyces cerevisiae extract; (ii) at least one compound selected from vitamin B3 and its derivatives; (iii) at least one divalent metal salt; and (iv) at least one monosaccharide selected from the group consisting of mannose, glucose, galactose, fructose, and combinations thereof. 2 . The composition according to claim 1 , wherein the Saccharomyces cerevisiae extract is an extract of yeast cells of Saccharomyces cerevisiae.

3. The composition according to claim 1 or 2, wherein the Saccharomyces cerevisiae extract is present in an amount of dry matter ranging from 0.001 wt.% to 0.375 wt.%, preferably from 0.01 wt.% to 0.175 wt.%, more preferably from 0.05 wt.% to 0.1 wt.%, relative to the total weight of the composition.

4. The composition according to any one of claims 1 to 3, wherein the compound selected from vitamin B3 and its derivatives is selected from niacinamide, nicotinic acid, nicotinyl alcohol, nicotinuric acid, nicotinyl hydroxamic acid, nicotinic acid esters, esters of nicotinyl alcohol with carboxylic acids, 2-chloronicotinamide, 6-methylnicotinamide, 6-aminonicotinamide, N-methylnicotinamide, N,N-dimethylnicotinamide, N-(hydroxymethyl)nicotinamide, quinolinic acid imide, nicotinanilide, N-benzylnicotinamide, N-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, nyalamid, 2-mercaptonicotinic acid, nicotinamide and nyprazine, methyl nicotinate and sodium nicotinate, and combinations thereof.

5. The composition according to any one of claims 1 to 4, wherein the compound selected from vitamin B3 and its derivatives is selected from niacinamide, niacin, nicotinic alcohol, nicotinuric acid, nicotinyl hydroxamic acid, and combinations thereof, preferably, the compound selected from vitamin B3 and its derivatives is niacinamide.

6. The composition according to any one of claims 1 to 5, wherein the compound selected from vitamin B3 and its derivatives is present in an amount ranging from 0.01 wt.% to 7 wt.%, preferably from 0.1 wt.% to 5 wt.%, more preferably from 0.5 wt.% to 3 wt.%, relative to the total weight of the composition.

7. The composition according to any one of claims 1 to 6, wherein the divalent metal salt comprises a metal ion M1 2+ , which is selected from Mg 2+ , Ca 2+ 、Zn 2+ and Cu 2+ .

8. The composition of any one of claims 1 to 7, wherein the divalent metal salt is selected from the group consisting of magnesium gluconate, magnesium aspartate, magnesium PCA, magnesium sulfate, magnesium acetate, magnesium carbonate, calcium carbonate, calcium PCA, calcium chloride, calcium carbonate, zinc PCA, zinc gluconate, copper PCA, copper gluconate, and mixtures thereof.

9. The composition according to any one of claims 1 to 8, wherein the divalent metal salt is present in an amount ranging from 0.00001 wt.% to 1 wt.%, preferably from 0.00005 wt.% to 0.5 wt.%, more preferably from 0.0001 wt.% to 0.1 wt.%, relative to the total weight of the composition.

10. The composition of any one of claims 1-9, wherein the monosaccharide is glucose.

11. The composition according to any one of claims 1 to 10, wherein the monosaccharide is present in an amount ranging from 0.01 wt.% to 2 wt.%, preferably from 0.05 wt.% to 1.5 wt.%, more preferably from 0.1 wt.% to 1 wt.%, relative to the total weight of the composition.

12. The composition according to claim 1, comprising, relative to the total weight of the composition: (i) 0.05 wt.% to 0.1 wt.% of at least one Saccharomyces cerevisiae extract; (ii) 0.5 wt.% to 3 wt.% of niacinamide; (iii) 0.0001 wt.% to 0.1 wt.% of at least one divalent metal salt selected from the group consisting of magnesium gluconate, magnesium aspartate, magnesium PCA, magnesium acetate, magnesium carbonate, calcium carbonate, calcium PCA, calcium chloride, calcium carbonate, zinc PCA, zinc gluconate, copper PCA, copper gluconate, and mixtures thereof; and (iv) 0.1 wt.% to 1 wt.% of glucose.

13. A cosmetic method for caring for keratin materials, comprising applying to said keratin materials a composition according to any one of claims 1 to 12.

Images